by Peter Ciszewski | Dec 14, 2020
John Hayslip, MD, executive medical director at AbbVie Pharmaceuticals discusses new data testing venetoclax and azacitidine in patients with acute myeloid leukemia (AML). AML is a blood cancer that most often occurs in people over the age of 40 years. Signs...
by Peter Ciszewski | Dec 13, 2020
Lisa Nachtigall, MD, Clinical Director, Neuroendocrine and Pituitary Clinical Center at Massachusetts General Hospital, and Associate Professor at Harvard Medical School discusses acromegaly and when physicians should suspect this rare disease. Acromegaly is a rare...
by Peter Ciszewski | Dec 12, 2020
William Wierda, MD, PhD, of the MD Anderson Cancer Center discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia (CLL) presented at ASH 2020. CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes, and...
by Peter Ciszewski | Dec 11, 2020
Othman Al-Sawaf, MD, of the University of Cologne discusses follow-up data from the phase 3 CLL14 trial suggesting venetoclax plus obinutuzumab to be an effective long-term treatment for chronic lymphocytic leukemia (CLL) patients ineligible for standard...
by Peter Ciszewski | Dec 11, 2020
John Hayslip, MD, executive medical director at AbbVie Pharmaceuticals discusses the latest data from the MURANO study presented at ASH 2020. The MURANO study compared the safety and efficacy of 6 months of treatment with venetoclax plus rituximab vs...
